Keywords
Last Name
Institution

Lale Kostakoglu

TitlePROFESSOR
InstitutionMount Sinai
DepartmentRadiology
Address

     Bibliographic 
     selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Kostakoglu L, Fardanesh R, Posner M, Som P, Rao S, Park E, Doucette J, Stein EG, Gupta V, Misiukiewicz K, Genden E. Early detection of recurrent disease by FDG-PET/CT leads to management changes in patients with squamous cell cancer of the head and neck. Oncologist. 2013; 18(10):1108-17.
      View in: PubMed
    2. Heiba S, Kolker D, Ong L, Sharma S, Travis A, Teodorescu V, Ellozy S, Kostakoglu L, Savitch I, Machac J. Dual-isotope SPECT/CT impact on hospitalized patients with suspected diabetic foot infection: saving limbs, lives, and resources. Nucl Med Commun. 2013 Sep; 34(9):877-84.
      View in: PubMed
    3. Grant BW, Jung SH, Johnson JL, Kostakoglu L, Hsi E, Byrd JC, Jones J, Leonard JP, Martin SE, Cheson BD. A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701. Cancer. 2013 Nov 1; 119(21):3797-804.
      View in: PubMed
    4. Kostakoglu L, Gallamini A. Interim 18F-FDG PET in Hodgkin lymphoma: would PET-adapted clinical trials lead to a paradigm shift? J Nucl Med. 2013 Jul; 54(7):1082-93.
      View in: PubMed
    5. Kostakoglu L. Radionuclide response assessment of breast cancer. Semin Nucl Med. 2013 Jul; 43(4):299-316.
      View in: PubMed
    6. Rangaswamy B, Fardanesh MR, Genden EM, Park EE, Fatterpekar G, Patel Z, Kim J, Som PM, Kostakoglu L. Improvement in the detection of locoregional recurrence in head and neck malignancies: F-18 fluorodeoxyglucose-positron emission tomography/computed tomography compared to high-resolution contrast-enhanced computed tomography and endoscopic examination. Laryngoscope. 2013 Nov; 123(11):2664-9.
      View in: PubMed
    7. Biggi A, Gallamini A, Chauvie S, Hutchings M, Kostakoglu L, Gregianin M, Meignan M, Malkowski B, Hofman MS, Barrington SF. International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers. J Nucl Med. 2013 May; 54(5):683-90.
      View in: PubMed
    8. Gallamini A, Kostakoglu L. Interim FDG-PET in Hodgkin lymphoma: a compass for a safe navigation in clinical trials? Blood. 2012 Dec 13; 120(25):4913-20.
      View in: PubMed
    9. Kostakoglu L, Schöder H, Johnson JL, Hall NC, Schwartz LH, Straus DJ, LaCasce AS, Jung SH, Bartlett NL, Canellos GP, Cheson BD. Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone? Leuk Lymphoma. 2012 Nov; 53(11):2143-50.
      View in: PubMed
    10. Gallamini A, Kostakoglu L. Positron emission tomography/computed tomography surveillance in patients with lymphoma: a fox hunt? Haematologica. 2012 Jun; 97(6):797-9.
      View in: PubMed
    11. Ko EC, Genden EM, Misiukiewicz K, Som PM, Kostakoglu L, Chen CT, Packer S, Kao J. Toxicity profile and clinical outcomes in locally advanced head and neck cancer patients treated with induction chemotherapy prior to concurrent chemoradiation. Oncol Rep. 2012 Feb; 27(2):467-74.
      View in: PubMed
    12. Cameron K, Golan S, Simpson W, Peti S, Roayaie S, Labow D, Kostakoglu L. Recurrent pancreatic carcinoma and cholangiocarcinoma: 18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT). Abdom Imaging. 2011 Aug; 36(4):463-71.
      View in: PubMed
    13. Son H, Khan SM, Rahaman J, Cameron KL, Prasad-Hayes M, Chuang L, Machac J, Heiba S, Kostakoglu L. Role of FDG PET/CT in staging of recurrent ovarian cancer. Radiographics. 2011 Mar-Apr; 31(2):569-83.
      View in: PubMed
    14. King KG, Kositwattanarerk A, Genden E, Kao J, Som PM, Kostakoglu L. Cancers of the oral cavity and oropharynx: FDG PET with contrast-enhanced CT in the posttreatment setting. Radiographics. 2011 Mar-Apr; 31(2):355-73.
      View in: PubMed
    15. Straus DJ, Johnson JL, LaCasce AS, Bartlett NL, Kostakoglu L, Hsi ED, Schöder H, Hall NC, Jung SH, Canellos GP, Schwartz LH, Takvorian RW, Juweid ME, Cheson BD. Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. Blood. 2011 May 19; 117(20):5314-20.
      View in: PubMed
    16. Elliott BM, Peti S, Osman K, Scigliano E, Lee D, Isola L, Kostakoglu L. Combining FDG-PET/CT with laboratory data yields superior results for prediction of relapse in multiple myeloma. Eur J Haematol. 2011 Apr; 86(4):289-98.
      View in: PubMed
    17. Son H, Heiba S, Kostakoglu L, Machac J. Extraperitoneal urine leak after renal transplantation: the role of radionuclide imaging and the value of accompanying SPECT/CT - a case report. BMC Med Imaging. 2010; 10:23.
      View in: PubMed
    18. Heiba SI, Kolker D, Mocherla B, Kapoor K, Jiang M, Son H, Rangaswamy B, Kostakoglu L, Savitch I, DaCosta M, Machac J. The optimized evaluation of diabetic foot infection by dual isotope SPECT/CT imaging protocol. J Foot Ankle Surg. 2010 Nov-Dec; 49(6):529-36.
      View in: PubMed
    19. Chu MM, Kositwattanarerk A, Lee DJ, Makkar JS, Genden EM, Kao J, Packer SH, Som PM, Kostakoglu L. FDG PET with contrast-enhanced CT: a critical imaging tool for laryngeal carcinoma. Radiographics. 2010 Sep; 30(5):1353-72.
      View in: PubMed
    20. Son H, Kositwattanarerk A, Hayes MP, Chuang L, Rahaman J, Heiba S, Machac J, Zakashansky K, Kostakoglu L. PET/CT evaluation of cervical cancer: spectrum of disease. Radiographics. 2010 Sep; 30(5):1251-68.
      View in: PubMed
    21. Kao J, Vu HL, Genden EM, Mocherla B, Park EE, Packer S, Som PM, Kostakoglu L. The diagnostic and prognostic utility of positron emission tomography/computed tomography-based follow-up after radiotherapy for head and neck cancer. Cancer. 2009 Oct 1; 115(19):4586-94.
      View in: PubMed
    22. Eloy JA, Brett EM, Fatterpekar GM, Kostakoglu L, Som PM, Desai SC, Genden EM. The significance and management of incidental [18F]fluorodeoxyglucose-positron-emission tomography uptake in the thyroid gland in patients with cancer. AJNR Am J Neuroradiol. 2009 Aug; 30(7):1431-4.
      View in: PubMed
    23. Kostakoglu L. [18F]fluorodeoxyglucose positron emission tomography in the management of lymphomas. Clin Lymphoma Myeloma. 2008 Oct; 8(5):273-6.
      View in: PubMed
    24. Lin FY, Genden EM, Lawson WL, Som P, Kostakoglu L. High uptake in schneiderian papillomas of the maxillary sinus on positron-emission tomography using fluorodeoxyglucose. AJNR Am J Neuroradiol. 2009 Feb; 30(2):428-30.
      View in: PubMed
    25. Kostakoglu L. Early prediction of response to therapy: the clinical implications in Hodgkin's and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging. 2008 Aug; 35(8):1413-20.
      View in: PubMed
    26. Burri RJ, Rangaswamy B, Kostakoglu L, Hoch B, Genden EM, Som PM, Kao J. Correlation of positron emission tomography standard uptake value and pathologic specimen size in cancer of the head and neck. Int J Radiat Oncol Biol Phys. 2008 Jul 1; 71(3):682-8.
      View in: PubMed
    27. Mocherla B, Kim J, Roayaie S, Kim S, Machac J, Kostakoglu L. FDG PET/CT imaging to rule out extrahepatic metastases before liver transplantation. Clin Nucl Med. 2007 Dec; 32(12):947-8.
      View in: PubMed
    28. Kelloff GJ, Sullivan DM, Wilson W, Cheson B, Juweid M, Mills GQ, Zelenetz AD, Horning SJ, Weber W, Sargent DJ, Dodd L, Korn E, Armitage J, Schilsky R, Christian M, O'connor OA, Wang SJ, Farrell AT, Pazdur R, Graham M, Wahl RL, Larson SM, Kostakoglu L, Daube-Witherspoon M, Gastonis C, Siegel BA, Shankar LK, Lee DB, Higley HR, Sigman CC, Carucci D, Timko D, deGennaro LJ, Sigal E, Barker A, Woodcock J. FDG-PET lymphoma demonstration project invitational workshop. Acad Radiol. 2007 Mar; 14(3):330-9.
      View in: PubMed
    29. Milowsky MI, Nanus DM, Kostakoglu L, Sheehan CE, Vallabhajosula S, Goldsmith SJ, Ross JS, Bander NH. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol. 2007 Feb 10; 25(5):540-7.
      View in: PubMed
    30. Mones JV, Coleman M, Kostakoglu L, Furman RR, Chadburn A, Shore TB, Muss D, Stewart P, Kroll S, Vallabhajosula S, Goldsmith SJ, Leonard JP. Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement. Leuk Lymphoma. 2007 Feb; 48(2):342-8.
      View in: PubMed
    31. Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, Wiseman GA, Kostakoglu L, Scheidhauer K, Buck A, Naumann R, Spaepen K, Hicks RJ, Weber WA, Reske SN, Schwaiger M, Schwartz LH, Zijlstra JM, Siegel BA, Cheson BD. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007 Feb 10; 25(5):571-8.
      View in: PubMed
    32. Kostakoglu L, Goldsmith SJ, Leonard JP, Christos P, Furman RR, Atasever T, Chandramouly A, Verma S, Kothari P, Coleman M. FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer. 2006 Dec 1; 107(11):2678-87.
      View in: PubMed
    33. Coleman M, Kostakoglu L. Early 18F-labeled fluoro-2-deoxy-D-glucose positron emission tomography scanning in the lymphomas: changing the paradigms of treatments? Cancer. 2006 Oct 1; 107(7):1425-8.
      View in: PubMed
    34. David KA, Milowsky MI, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Nanus DM, Bander NH. Clinical utility of radiolabeled monoclonal antibodies in prostate cancer. Clin Genitourin Cancer. 2006 Mar; 4(4):249-56.
      View in: PubMed
    35. Dosik AD, Coleman M, Kostakoglu L, Furman RR, Fiore JM, Muss D, Niesvizky R, Shore T, Schuster MW, Stewart P, Vallabhajosula S, Goldsmith SJ, Leonard JP. Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma. Cancer. 2006 Feb 1; 106(3):616-22.
      View in: PubMed
    36. Kostakoglu L, Goldsmith SJ. Lymphoma imaging: nuclear medicine. Cancer Treat Res. 2006; 131:363-412.
      View in: PubMed
    37. Vallabhajosula S, Goldsmith SJ, Kostakoglu L, Milowsky MI, Nanus DM, Bander NH. Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity. Clin Cancer Res. 2005 Oct 1; 11(19 Pt 2):7195s-7200s.
      View in: PubMed
    38. Leonard JP, Coleman M, Kostakoglu L, Chadburn A, Cesarman E, Furman RR, Schuster MW, Niesvizky R, Muss D, Fiore J, Kroll S, Tidmarsh G, Vallabhajosula S, Goldsmith SJ. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. J Clin Oncol. 2005 Aug 20; 23(24):5696-704.
      View in: PubMed
    39. Vallabhajosula S, Goldsmith SJ, Hamacher KA, Kostakoglu L, Konishi S, Milowski MI, Nanus DM, Bander NH. Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen. J Nucl Med. 2005 May; 46(5):850-8.
      View in: PubMed
    40. Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol. 2005 Jul 20; 23(21):4591-601.
      View in: PubMed
    41. Vallabhajosula S, Kuji I, Hamacher KA, Konishi S, Kostakoglu L, Kothari PA, Milowski MI, Nanus DM, Bander NH, Goldsmith SJ. Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu? J Nucl Med. 2005 Apr; 46(4):634-41.
      View in: PubMed
    42. Kostakoglu L, Hardoff R, Mirtcheva R, Goldsmith SJ. PET-CT fusion imaging in differentiating physiologic from pathologic FDG uptake. Radiographics. 2004 Sep-Oct; 24(5):1411-31.
      View in: PubMed
    43. Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Bander NH. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol. 2004 Jul 1; 22(13):2522-31.
      View in: PubMed
    44. Goldsmith SJ, Kostakoglu LA, Somrov S, Palestro CJ. Radionuclide imaging of thoracic malignancies. Thorac Surg Clin. 2004 Feb; 14(1):95-112.
      View in: PubMed
    45. Kostakoglu L, Leonard JP, Coleman M, Goldsmith SJ. The role of FDG-PET imaging in the management of lymphoma. Clin Adv Hematol Oncol. 2004 Feb; 2(2):115-21.
      View in: PubMed
    46. Kostakoglu L, Goldsmith SJ. PET in the assessment of therapy response in patients with carcinoma of the head and neck and of the esophagus. J Nucl Med. 2004 Jan; 45(1):56-68.
      View in: PubMed
    47. Nanus DM, Milowsky MI, Kostakoglu L, Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, Bander NH. Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen. J Urol. 2003 Dec; 170(6 Pt 2):S84-8; discussion S88-9.
      View in: PubMed
    48. Bander NH, Trabulsi EJ, Kostakoglu L, Yao D, Vallabhajosula S, Smith-Jones P, Joyce MA, Milowsky M, Nanus DM, Goldsmith SJ. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urol. 2003 Nov; 170(5):1717-21.
      View in: PubMed
    49. Bander NH, Nanus DM, Milowsky MI, Kostakoglu L, Vallabahajosula S, Goldsmith SJ. Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Semin Oncol. 2003 Oct; 30(5):667-76.
      View in: PubMed
    50. Kostakoglu L, Agress H, Goldsmith SJ. Clinical role of FDG PET in evaluation of cancer patients. Radiographics. 2003 Mar-Apr; 23(2):315-40; quiz 533.
      View in: PubMed
    51. Kostakoglu L, Goldsmith SJ. 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma. J Nucl Med. 2003 Feb; 44(2):224-39.
      View in: PubMed
    52. Yao D, Trabulsi EJ, Kostakoglu L, Vallabhajosula S, Joyce MA, Nanus DM, Milowsky M, Liu H, Goldsmith SJ. The utility of monoclonal antibodies in the imaging of prostate cancer. Semin Urol Oncol. 2002 Aug; 20(3):211-8.
      View in: PubMed
    53. Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med. 2002 Aug; 43(8):1018-27.
      View in: PubMed
    54. Kostakoglu L. Noninvasive detection of multidrug resistance in patients with hematological malignancies: are we there yet? Clin Lymphoma. 2002 Mar; 2(4):242-8.
      View in: PubMed
    55. Kostakoglu L, Leonard JP, Kuji I, Coleman M, Vallabhajosula S, Goldsmith SJ. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma. Cancer. 2002 Feb 15; 94(4):879-88.
      View in: PubMed
    56. Kostakoglu L, Goldsmith SJ. Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma: is it time to shift gears? Eur J Nucl Med. 2000 Oct; 27(10):1564-78.
      View in: PubMed
    57. Ercan MT, Kostakoglu L. Radiopharmaceuticals for the visualization of infectious and inflammatory lesions. Curr Pharm Des. 2000 Jul; 6(11):1159-77.
      View in: PubMed
    58. Kostakoglu L, Goldsmith SJ. Positron emission tomography in lymphoma: comparison with computed tomography and Gallium-67 single photon emission computed tomography. Clin Lymphoma. 2000 Jun; 1(1):67-74; discussion 75-6.
      View in: PubMed
    59. Goldsmith SJ, Kostakoglu L. Nuclear medicine imaging of lung cancer. Radiol Clin North Am. 2000 May; 38(3):511-24.
      View in: PubMed
    60. Goldsmith SJ, Kostakoglu L. Role of nuclear medicine in the evaluation of the solitary pulmonary nodule. Semin Ultrasound CT MR. 2000 Apr; 21(2):129-38.
      View in: PubMed
    61. Gülaldi NC, Kostakoglu L, Uzal D, Hayran M, Elahi N, Uysal U, Aktas A, Atahan L, Bekdik C. Impact of radiotherapy on normal brain tissue: semi-automated quantification of decrease in perfusion. Ann Nucl Med. 2000 Feb; 14(1):17-23.
      View in: PubMed
    62. Yazici KM, Kostakoglu L. Cerebral blood flow changes in patients with conversion disorder. Psychiatry Res. 1998 Sep 28; 83(3):163-8.
      View in: PubMed
    63. Kostakoglu L, Guc D, Canpinar H, Kars A, Alper E, Kiratli P, Hayran M, Gündüz U, Kansu E. P-glycoprotein expression by technetium-99m-MIBI scintigraphy in hematologic malignancy. J Nucl Med. 1998 Jul; 39(7):1191-7.
      View in: PubMed
    64. Kostakoglu L, Ruacan S, Ergün EL, Sayek I, Elahi N, Bekdik CF. Influence of the heterogeneity of P-glycoprotein expression on technetium-99m-MIBI uptake in breast cancer. J Nucl Med. 1998 Jun; 39(6):1021-6.
      View in: PubMed
    65. Kostakoglu L, Kiratli P, Ruacan S, Hayran M, Emri S, Ergün EL, Bekdik CF. Association of tumor washout rates and accumulation of technetium-99m-MIBI with expression of P-glycoprotein in lung cancer. J Nucl Med. 1998 Feb; 39(2):228-34.
      View in: PubMed
    66. Kostakoglu L, Elahi N, Uzal D, Khademi B, Atahan L, Bekdik CF. Double-phase Tc-99m-SestaMIBI SPECT imaging in a case of glomus jugulare tumor. Radiat Med. 1997 Sep-Oct; 15(5):331-4.
      View in: PubMed
    67. Kostakoglu L, Uysal U, Ozyar E, Hayran M, Uzal D, Demirkazïk FB, Kars A, Atahan L, Bekdik CF. Monitoring response to therapy with thallium-201 and technetium-99m-sestamibi SPECT in nasopharyngeal carcinoma. J Nucl Med. 1997 Jul; 38(7):1009-14.
      View in: PubMed
    68. Kostakoglu L, Elahi N, Kïratlï P, Ruacan S, Sayek I, Baltalï E, Sungur A, Hayran M, Bekdik CF. Clinical validation of the influence of P-glycoprotein on technetium-99m-sestamibi uptake in malignant tumors. J Nucl Med. 1997 Jul; 38(7):1003-8.
      View in: PubMed
    69. Kostakoglu L, Uysal U, Ozyar E, Demirkazik FB, Hayran M, Atahan L, Bekdik CF. A comparative study of technetium-99m sestamibi and technetium-99m tetrofosmin single-photon tomography in the detection of nasopharyngeal carcinoma. Eur J Nucl Med. 1997 Jun; 24(6):621-8.
      View in: PubMed
    70. Kiratli PO, Kiratli H, Ercan MT, Kostakoglu L. Visualization of uveal amelanotic melanoma with technetium-99m(V) dimercaptosuccinic acid. Ann Nucl Med. 1997 May; 11(2):147-9.
      View in: PubMed
    71. Uysal U, Kostakoglu L, Elahi N, Aydingöz U, Firat D, Bekdik CF. Can bone scintigraphy detect additional metastatic sites unrevealed by CT in patients with recurrent ovarian carcinoma? Radiat Med. 1997 Jan-Feb; 15(1):55-8.
      View in: PubMed
    72. Kostakoglu L, Uysal U, Ozyar E, Elahi N, Hayran M, Uzal D, Demirkazik FB, Kars A, Ugur O, Atahan L, Bekdik CF. Pre- and post-therapy thallium-201 and technetium-99m-sestamibi SPECT in nasopharyngeal carcinoma. J Nucl Med. 1996 Dec; 37(12):1956-62.
      View in: PubMed
    73. Kostakoglu L, Wong JC, Barrington SF, Cronin BF, Dynes AM, Maisey MN. Speech-related visualization of laryngeal muscles with fluorine-18-FDG. J Nucl Med. 1996 Nov; 37(11):1771-3.
      View in: PubMed
    74. Kostakoglu L, Panicek DM, Divgi CR, Botet J, Healy J, Larson SM, Abdel-Dayem HM. Correlation of the findings of thallium-201 chloride scans with those of other imaging modalities and histology following therapy in patients with bone and soft tissue sarcomas. Eur J Nucl Med. 1996 Nov; 23(11):1558.
      View in: PubMed
    75. Kostakoglu L, Ozyar E, Uysal U, Elahi N, Uzal D, Kars A, Atahan L, Bekdik CF. Influence of immediate post-therapy bone scintigraphy in the assessment of response to therapy in a case of nasopharyngeal carcinoma. Radiat Med. 1996 Sep-Oct; 14(5):279-81.
      View in: PubMed
    76. Ugur O, Caner B, Cekirge S, Balkanci F, Ergün EL, Kostakoglu L, Bekdik C. The diagnosis of renovascular hypertension with technetium-99m-ethylenedicysteine captopril scintigraphy. Invest Radiol. 1996 Aug; 31(8):497-501.
      View in: PubMed
    77. Ugur O, Caner B, Cekirge S, Balkanci F, Ergün EL, Kostakoglu L, Aras T, Bekdik C. Technetium-99m-ethylenedicysteine in the diagnosis and follow-up of renovascular hypertension. Invest Radiol. 1996 Jun; 31(6):378-81.
      View in: PubMed
    78. Ugur O, Kostakoglu L, Caner B, Güler N, Gülaldi NC, Ozmen M, Uysal U, Elahi N, Erbengi G, Bejdik C. Comparison of 201Tl, 99Tcm-MIBI and 131I imaging in the follow-up of patients with well-differentiated thyroid carcinoma. Nucl Med Commun. 1996 May; 17(5):373-7.
      View in: PubMed
    79. Grant SC, Kostakoglu L, Kris MG, Yeh SD, Larson SM, Finn RD, Oettgen HF, Cheung NV. Targeting of small-cell lung cancer using the anti-GD2 ganglioside monoclonal antibody 3F8: a pilot trial. Eur J Nucl Med. 1996 Feb; 23(2):145-9.
      View in: PubMed
    80. Ugur O, Kostakoglu L, Hui ET, Fisher DR, Garmestani K, Gansow OA, Cheung NK, Larson SM. Comparison of the targeting characteristics of various radioimmunoconjugates for radioimmunotherapy of neuroblastoma: dosimetry calculations incorporating cross-organ beta doses. Nucl Med Biol. 1996 Jan; 23(1):1-8.
      View in: PubMed
    81. Kostakoglu L, Panicek DM, Divgi CR, Botet J, Healey J, Larson SM, Abdel-Dayem HM. Correlation of the findings of thallium-201 chloride scans with those of other imaging modalities and histology following therapy in patients with bone and soft tissue sarcomas. Eur J Nucl Med. 1995 Nov; 22(11):1232-7.
      View in: PubMed
    82. Divgi CR, Scott AM, Dantis L, Capitelli P, Siler K, Hilton S, Finn RD, Kemeny N, Kelsen D, Kostakoglu L, et al. Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colon carcinoma. J Nucl Med. 1995 Apr; 36(4):586-92.
      View in: PubMed
    83. Ugur O, Scott AM, Kostakoglu L, Hui TE, Masterson ME, Febo R, Sgouros G, Rosa E, Mehta BM, Fisher DR, et al. Calculated and TLD-based absorbed dose estimates for I-131-labeled 3F8 monoclonal antibody in a human neuroblastoma xenograft nude mouse model. Nucl Med Biol. 1995 Jan; 22(1):87-93.
      View in: PubMed
    84. Kostakoglu L, Roistacher N, Kalaigian H, Larson SM, Abdel-Dayem H. Simultaneous gallium-67 citrate and technetium-99m sestamibi SPET in a case of myocardial lymphoma: comparison with echocardiography before and after chemotherapy. Eur J Nucl Med. 1994 Sep; 21(9):1013-6.
      View in: PubMed
    85. Larson SM, Divgi CR, Scott A, Sgouros G, Graham MC, Kostakoglu L, Scheinberg D, Cheung NK, Schlom J, Finn RD. Current status of radioimmunotherapy. Nucl Med Biol. 1994 Jul; 21(5):785-92.
      View in: PubMed
    86. Kostakoglu L, Divgi CR, Hilton S, Cordon-Cardo C, Scott AM, Kalaigian H, Finn RD, Schlom J, Larson SM. Preselection of patients with high TAG-72 antigen expression leads to targeting of 94% of known metastatic tumor sites with monoclonal antibody I-131-CC49. Cancer Invest. 1994; 12(6):551-8.
      View in: PubMed
    87. Rubin SC, Kostakoglu L, Divgi C, Federici MG, Finstad CL, Lloyd KO, Larson SM, Hoskins WJ. Biodistribution and intraoperative evaluation of radiolabeled monoclonal antibody MX35 in patients with epithelial ovarian cancer. Gynecol Oncol. 1993 Oct; 51(1):61-6.
      View in: PubMed
    88. Caluser C, Healey J, Macapinlac H, Kostakoglu L, Abdel-Dayem HM, Larson SM, Yeh SD. Tl-201 uptake in recurrent pigmented villonodular synovitis. Correlation with three-phase bone imaging. Clin Nucl Med. 1992 Sep; 17(9):751-3.
      View in: PubMed
    89. Caluser C, Macapinlac H, Healey J, Ghavimi F, Meyers P, Wollner N, Kalaigian J, Kostakoglu L, Abdel-Dayem HM, Yeh SD, et al. The relationship between thallium uptake, blood flow, and blood pool activity in bone and soft tissue tumors. Clin Nucl Med. 1992 Jul; 17(7):565-72.
      View in: PubMed
    90. Scott AM, Kostakoglu L, O'Brien JP, Straus DJ, Abdel-Dayem HM, Larson SM. Comparison of technetium-99m-MIBI and thallium-201-chloride uptake in primary thyroid lymphoma. J Nucl Med. 1992 Jul; 33(7):1396-8.
      View in: PubMed
    91. Kostakoglu L, Yeh SD, Portlock C, Heelan R, Yao TJ, Niedzwiecki D, Larson SM. Validation of gallium-67-citrate single-photon emission computed tomography in biopsy-confirmed residual Hodgkin's disease in the mediastinum. J Nucl Med. 1992 Mar; 33(3):345-50.
      View in: PubMed
    Kostakoglu's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts
    _
    Co-Authors
    _
    Similar People
    _
    Same Department
     
    Mount Sinai Profiles is managed by Conduits - The Institutes for Translational Sciences at Icahn School of Medicine, supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences of the National Institutes of Health through Grant Number UL1TR000067